256 research outputs found

    Análisis de Las Capacidades Emprendedoras Potenciales y Efectivas en Alumnos de Centros de Educación Superior

    Get PDF
    There were identified four factors that determine the enterprising potential capacity of a pupil belonging to higher education centers (attributes of the entrepreneur, interpersonal capacities, capacities opposite to the risk and attitude of the entrepreneur). On having organized into a hierarchy using the AHP method, it concluded the vectors of priority giving a major importance for attitude and attributes of the entrepreneur, which as a whole represent 76%. The index of enterprising potential capacity was 74% and the percentage of pupils with effective enterprising capacity was 16%. This gap of development of enterprising capacity represents a strategic challenge for each higher education centers, to contribute to its value and in addition to the local, regional and national development. There proposes a model of analysis of the enterprising capacities, who would allow significant achievements in the formation of effective enterprising capacities

    First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>The prevalence of infections with <it>Mycobacterium tuberculosis </it>(MTb) and nontuberculous mycobacteria (NTM) species in HIV-infected patients in Mexico is unknown. The aims of this study were to determine the frequency of MTb and NTM species in HIV-infected patients from Mexico City, to evaluate the genotypic diversity of the <it>Mycobacterium tuberculosis </it>complex strains, to determine their drug resistance profiles by colorimetric microplate Alamar Blue assay (MABA), and finally, to detect mutations present in <it>kat</it>G, <it>rpo</it>B and <it>inh</it>A genes, resulting in isoniazid (INH) and rifampin (RIF) resistance.</p> <p>Results</p> <p>Of the 67 mycobacterial strains isolated, 48 were identified as MTb, 9 as <it>M. bovis</it>, 9 as <it>M. avium </it>and 1 as <it>M. intracellulare</it>. IS<it>6110</it>-RFLP of 48 MTb strains showed 27 profiles. Spoligotyping of the 48 MTb strains yielded 21 patterns, and 9 <it>M. bovis </it>strains produced 7 patterns. Eleven new spoligotypes patterns were found. A total of 40 patterns were produced from the 48 MTb strains when MIRU-VNTR was performed. Nineteen (39.6%) MTb strains were resistant to one or more drugs. One (2.1%) multidrug-resistant (MDR) strain was identified. A novel mutation was identified in a RIF-resistant strain, GAG ‚Üí TCG (Glu ‚Üí Ser) at codon 469 of <it>rpo</it>B gene.</p> <p>Conclusions</p> <p>This is the first molecular analysis of mycobacteria isolated from HIV-infected patients in Mexico, which describe the prevalence of different mycobacterial species in this population. A high genetic diversity of MTb strains was identified. New spoligotypes and MIRU-VNTR patterns as well as a novel mutation associated to RIF-resistance were found. This information will facilitate the tracking of different mycobacterial species in HIV-infected individuals, and monitoring the spread of these microorganisms, leading to more appropriate measures for tuberculosis control.</p

    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    Get PDF
    Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18‚Äď85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25‚Äď75 mL/min per 1¬∑73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300‚Äď5000 mg/g who had received maximum labelled or tolerated renin‚Äďangiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0¬∑75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0¬∑75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ‚Č•30 days)or end-stage kidney disease (eGFR <15 mL/min per 1¬∑73 m 2 sustained for ‚Č•90 days, chronic dialysis for ‚Č•90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2¬∑2 years (IQR 1¬∑4‚Äď2¬∑9). 79 (6¬∑0%)of 1325 patients in the atrasentan group and 105 (7¬∑9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0¬∑65 [95% CI 0¬∑49‚Äď0¬∑88]; p=0¬∑0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3¬∑5%)of 1325 patients in the atrasentan group and 34 (2¬∑6%)of 1323 patients in the placebo group (HR 1¬∑33 [95% CI 0¬∑85‚Äď2¬∑07]; p=0¬∑208). 58 (4¬∑4%)patients in the atrasentan group and 52 (3¬∑9%)in the placebo group died (HR 1¬∑09 [95% CI 0¬∑75‚Äď1¬∑59]; p=0¬∑65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

    Long-range angular correlations on the near and away side in p&#8211;Pb collisions at

    Get PDF

    Search for dark matter produced in association with bottom or top quarks in ‚ąös = 13 TeV pp collisions with the ATLAS detector